Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (NCT06079190)
A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — San Diego, California
Age range: 50 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (97 Sites)
Showing the first 25 of 97 sites.
- GSK Investigational Site — San Diego, California
- GSK Investigational Site — Lake Mary, Florida
- GSK Investigational Site — Lake Worth, Florida
- GSK Investigational Site — Maitland, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Stuart, Florida
- GSK Investigational Site — The Villages, Florida
- GSK Investigational Site — The Villages, Florida
- GSK Investigational Site — Decatur, Georgia
- GSK Investigational Site — Elk Grove Village, Illinois
- GSK Investigational Site — Chesterfield, Missouri
- GSK Investigational Site — Toms River, New Jersey
- GSK Investigational Site — Staten Island, New York
- GSK Investigational Site — Matthews, North Carolina
- GSK Investigational Site — North Canton, Ohio
- GSK Investigational Site — Oklahoma City, Oklahoma
- GSK Investigational Site — Portland, Oregon
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Fairfax, Virginia
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Ciudad Autonoma de Buenos Aire,
- GSK Investigational Site — Ciudad Autonoma de Bueno,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.